-
Sector Analysis
Menopausal Disorders (MD) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Menopausal Disorders (MD) Marketed and Pipeline Drugs Report Overview Menopausal disorders are a permanent cessation of menstruation resulting in the loss of ovarian follicle development. In 2023, the highest number of prevalent cases of menopausal disorders were registered in India and China. Treatment guidelines for MD are well-established globally and at the country level and are updated periodically. For instance, in 2023, the US and China updated guidelines. In the US, guidelines were provided by the North American Menopause Society...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – DSP-107 in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - DSP-107 in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. DSP-107 in Non-Small Cell Lung Cancer Drug Details: DSP-107 (KAHR-107)...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – DSP-107 in Squamous Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - DSP-107 in Squamous Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. DSP-107 in Squamous Non-Small Cell Lung Cancer Drug Details:...
-
Product Insights
NewLikelihood of Approval Analysis for Macular Degeneration
Overview How likely is it that the drugs in Macular Degeneration will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Macular Degeneration Overview Macular degeneration is primarily an age-related retinal condition. There...
-
Product Insights
NewLikelihood of Approval Analysis for Chronic Myelomonocytic Leukemia (CMML)
Overview How likely is it that the drugs in Chronic Myelomonocytic Leukemia (CMML) will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Chronic Myelomonocytic Leukemia (CMML) Overview Chronic Myelomonocytic Leukemia (CMML) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Azacitidine in Pancreatic Ductal Adenocarcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Azacitidine in Pancreatic Ductal Adenocarcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Azacitidine in Pancreatic Ductal Adenocarcinoma Drug Details: Azacitidine (Vidaza, Azafuridine, Celazadine)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Azacitidine in Peripheral T-Cell Lymphomas (PTCL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Azacitidine in Peripheral T-Cell Lymphomas (PTCL) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Azacitidine in Peripheral T-Cell Lymphomas (PTCL) Drug Details: Azacitidine (Vidaza,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Azacitidine in Diffuse Large B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Azacitidine in Diffuse Large B-Cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Azacitidine in Diffuse Large B-Cell Lymphoma Drug Details: Azacitidine (Vidaza,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Azacitidine in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Azacitidine in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Azacitidine in Acute Myelocytic Leukemia (AML, Acute...